Biovitrum Initiates Phase I Clinical Trials for Its Novel Class Type II Diabetes Compound STOCKHOLM, Sweden, March 11, 2002 (PRIMEZONE) -- Biovitrum today announced that it has entered Phase I studies with BVT.3498, a selective 11B HSD-1 inhibitor for the treatment of Type II...